Found 2 articles for: "PASI"
Deucravacitinib With Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis
August 2025 | Volume 24 | Issue 8 | Original Article | 744 | Copyright © August 2025
Background: To assess the effectiveness, safety, and quality of life in patients who received topical calcipotriene/betamethasone dipropionate (C/BD) foam added to oral deucravacitini...
Read MoreGuselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses
February 2025 | Volume 24 | Issue 2 | Original Article | 196 | Copyright © February 2025
Background: The pivotal Phase 3 VOYAGE 1 and VOYAGE 2 studies established the robust efficacy and safety of guselkumab for up to 5 years in patients with moderate-to-severe psori...
Read More
